The research on the expansion of the combination of Diosmin and Hesperidin mainly focuses on the aspects of anti-inflammatory, anti-allergic, hypolipidemic, anticancer and optimization of drug formulation, etc. The following is the specific analysis:
Expansion of anti-inflammatory and anti-allergic effects: Hesperidin can reduce the symptoms of allergy and hay fever by inhibiting the production of histamine in the bloodstream, and when used in combination with diosmin, the two produce a synergistic effect in anti-inflammation. In vitro and in vivo studies have shown that the combination provides significant protection against inflammatory diseases, with possible mechanisms including inhibition of arachidonic acid-like synthesis and antioxidant radical scavenger effects.
Hypolipidemic and cardiovascular protection studies: Hesperidin, as a flavonoid compound with hypolipidemic and vasoprotective properties, further enhances the protective effects on the circulatory system when used in combination with diosmin. This synergistic effect may be realized through mechanisms such as improving blood flow, reducing blood viscosity, and accelerating blood flow rate, providing new therapeutic strategies for cardiovascular disease prevention.
Exploration of anticancer activity: Hesperidin and its glycoside hesperidin have demonstrated anticancer effects, and the combination with diosmin may enhance the anticancer effect through mechanisms such as inhibiting cell proliferation and inducing apoptosis. Existing studies have shown that this combination can inhibit tumorigenesis induced by a variety of carcinogens, and dose optimization and mechanism of action studies can be carried out for different types of cancer in the future.
Optimization of drug formulation: Micronization technology has increased the absorption rate of mixtures of diosmin and hesperidin (MPFF) to twice that of non-micronized formulations, significantly improving the bioavailability of the drug. In the future, new delivery systems such as nanocarriers and liposomes can be explored to further improve drug targeting and efficacy.
Expansion of clinical applications: The combination has been approved for the treatment of venous insufficiency and hemorrhoids in Europe. Subsequent studies could focus on new indications such as diabetic microangiopathy, postoperative edema, and premenstrual syndrome. Its efficacy and safety in different diseases can be systematically evaluated by conducting multi-center RCT studies.